课件：转移性结直肠癌治疗的新进展_.ppt

* New Developments in the Treatment of Colorectal Cancer * * * FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; mFOLFOX, modified 5-fluorouracil, leucovorin, and oxaliplatin; sLV5FU2, simplified leucovorin plus bolus and infusional fluorouracil. * OS, overall survival; PFS, progression-free survival. * * * * ECOG, Eastern Cooperative Oncology Group; mCRC, metastatic colorectal cancer; PS, performance score; q3w, every 3 weeks. * * * Bev, bevacizumab; ITT, intention to treat; XELOX, capecitabine, oxaliplatin. * CR, complete response; FOLFIRI, leucovorin/fluorouracil/irinotecan; mCRC, metastatic colorectal cancer; PR, partial response; SD, stable disease. * * OS, overall survival; PFS, progression-free survival. * * 5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; IV, intravenously; LV, leucovorin; mCRC, metastatic colorectal cancer; q2w, every 2 weeks; XRT, external-beam radiotherapy. * * Bev, bevacizumab; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; mCRC, metastatic colorectal cancer; OS, overall survival. * * 5-FU, 5-fluorouracil; BEV, bevacizumab; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; mCRC, metastatic colorectal cancer; OS, overall survival; PD, progressive disease; PFS, progression-free survival. * CT, chemotherapy; BEV, bevacizumab; ECOG, Eastern Cooperative Oncology Group; ITT, intent to treat; OS, overall survival; PFS, progression-free survival; PS, performance score. * * * * ECOG, Eastern Cooperative Oncology Group; FOLFIRI, fluorouracil/leucovorin/irinotecan; mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; q2w, once every 2 weeks; PFS, progression-free survival; PS, performance status. * * FOLFIRI, fluorouracil/leucovorin/irinotecan; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival. * * AFL, aflibercept; FOLFIRI, fluorouracil/leucovorin/irin